Skip to main content
. 2017 Mar 11;19:54. doi: 10.1186/s13075-017-1263-7

Table 1.

Drugs obtained and their biological targets

Scorea Biological target Action Drugs p value
+ Topoisomerase II Inhibitor Amsacrine, amonafide, teniposide, etoposide, idarubicin 2.829 × 10–4
+ HDAC Inhibitor Panobinostat, scriptaid, dacinostat, vorinostat, trichostatin A 1.451 × 10–4
+ Protein kinase C delta Activator Phorbol-12-myristate-13-acetate, ingenol 3.172 × 10–3
+ Histone lysine methyltransferase Inhibitor Chaetocin
+ ARFGAP1 Inhibitor QS11
+ PDK1 Inhibitor BX795
+ Retinoic acid receptor beta Inhibitor Le135
+ Arginase Inhibitor Inhibitor Bec
+ JAK2/STAT3 Inhibitor Cucurbitacin I
+ Fatty acid synthetase Inhibitor Cerulenin
+ Src, Bcr-Abl tyrosine kinase Inhibitor AG957
+ PLD2 Inhibitor CAY10594
+ IKKβ Inhibitor Parthenolide
+ IMPDH1 Inhibitor Mycophenolic acid
+ FTL3 Inhibitor Midostaurin
+ DNA Crosslinker Mitomycin C
+ Tubulin Inhibitor Vinblastine
+ Hsp90 Inhibitor Radicol
+ Multiple targets Inhibitor Resveratrol
PI3K Inhibitor PI828, GDC0941, NVP-BEZ235,PP110, TGX115 4.915 × 10–6
mTOR Inhibitor NVP-BEZ235, AZD8055, TGX115, Ku0063794 1.792 × 10–5
CDK Inhibitor BML259, indirubin 1.463 × 10–2
IKBalfa Inhibitor Evodiamine
Farnesyltransferase Inhibitor Tipifarnib
IGF1R Inhibitor Linsitinib
MAP2K1 Inhibitor Selumetinib
CHK1 Inhibitor SB218078
Piruvate kinase Inhibitor M2PK activator
Rho kinase Inhibitor Rho kinase inhibitor III
Voltage-dependent calcium channel Inhibitor Nifedipine
Braf Inhibitor Vemurafenib

Table presents significant drugs with their biological target and their mechanism of action. p value calculated for groups of drugs with the same target using Fisher’s exact test

CDK cyclin-dependent kinase, HDAC histone deacetylase, mTOR mammalian target of rapamycin, PI3K phosphoinositol 3 kinase

a+ drugs with positive similarity score, drugs with negative similarity score in regard to SLE signatures